Want to see IMUX full AI Analyst Report?
Immunic (IMUX) AI Stock Analysis
Immunic
(NASDAQ:IMUX)
The score is primarily weighed down by weak financial performance (no revenue, sizable losses, and significant cash burn) and bearish technical conditions (price well below key moving averages with negative MACD). Valuation contributes little support due to a negative P/E and no dividend yield data.
Immunic (IMUX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $100.15M
- Dividend Yield
- ―
- Average Volume (3M)
- 338.83K
- Price to Earnings (P/E)
- -1.5
- Beta (1Y)
- 0.74
- Revenue Growth
- ―
- EPS Growth
- 50.66%
- Country
- US
- Employees
- 100
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Immunic Business Overview & Revenue Model
Company Description
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838...
Immunic Earnings Call Summary
The earnings call presented significant positive developments, including strengthened leadership, progress in key clinical trials, and potential market impact of vidofludimus calcium. However, challenges such as increased R&D expenses and net losses were also noted. The sentiment leans slightly positive due to the promising clinical trial results and potential market opportunities.
Q3-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Q3 2024 earnings call for Immunic, the company provided several key metrics and guidance concerning its financial status and clinical development programs. Immunic ended the quarter with $59.1 million in cash, which is expected to fund operations into Q3 2025. R&D expenses were reported at $21.4 million for the quarter, reflecting an increase from the previous year due to costs associated with clinical trials, offset by savings from deprioritized programs. The net loss for the quarter was approximately $24.4 million or $0.24 per share. Significant clinical milestones were also discussed, including the anticipated top-line data from the Phase II CALLIPER trial in progressive MS expected in April 2025, and the continuation of the Phase III ENSURE trials in relapsing MS, with the first trial completion expected by Q2 2026. The company also highlighted ongoing interest from pharmaceutical companies for potential partnerships, driven by the innovative profile and market potential of their lead asset, vidofludimus calcium.
Immunic Financial Statement Overview
Summary
Income statement and cash flow are very weak: zero revenue, large recurring losses (TTM net loss ~$111.6M), and heavy cash burn (TTM operating cash flow ~-$87.7M; free cash flow ~-$88.0M). The balance sheet is a relative positive with minimal debt (~$0.3M) and a return to positive equity in TTM (~$127.6M), but the business remains financing-dependent.
Income Statement
12Very NegativeBalance Sheet
58NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -33.00K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -111.42M | -97.00M | -100.37M | -93.50M | -86.44M | -92.86M |
| Net Income | -111.57M | -97.17M | -100.51M | -93.61M | -120.41M | -92.94M |
Balance Sheet | ||||||
| Total Assets | 159.17M | 24.05M | 40.87M | 54.30M | 127.75M | 139.10M |
| Cash, Cash Equivalents and Short-Term Investments | 155.10M | 15.48M | 35.67M | 46.67M | 116.37M | 86.86M |
| Total Debt | 567.00K | 684.00K | 1.00M | 1.33M | 1.56M | 992.00K |
| Total Liabilities | 31.59M | 30.73M | 22.44M | 25.37M | 14.07M | 11.98M |
| Stockholders Equity | 127.58M | -6.67M | 18.43M | 28.93M | 113.68M | 127.11M |
Cash Flow | ||||||
| Free Cash Flow | -88.05M | -85.97M | -85.03M | -71.16M | -65.26M | -83.30M |
| Operating Cash Flow | -87.72M | -85.81M | -84.77M | -70.83M | -65.14M | -83.23M |
| Investing Cash Flow | -329.00K | -161.00K | -264.00K | 9.46M | -9.74M | -67.00K |
| Financing Cash Flow | 188.82M | 65.58M | 74.54M | 1.03M | 95.76M | 42.84M |
Immunic Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMUX, the sentiment is Negative. The current price of 7.34 is below the 20-day moving average (MA) of 7.44, below the 50-day MA of 10.07, and below the 200-day MA of 11.50, indicating a bearish trend. The MACD of -0.62 indicates Negative momentum. The RSI at 38.64 is Neutral, neither overbought nor oversold. The STOCH value of 47.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMUX.
Immunic Risk Analysis
Immunic disclosed 78 risk factors in its most recent earnings report. Immunic reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksImmunic Peers Comparison
Overall Rating
VTVT49Neutral
HOWL47Neutral
EQ46Neutral
NRXP45Neutral- IMUX43Neutral
ATYR41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VTVT | 49Neutral | $99.52M | -219.54 | -6.27% | ― | 216600.00% | 75.57% |
| HOWL | 47Neutral | $47.92M | -1.43 | -166.98% | ― | ― | 55.37% |
| EQ | 46Neutral | $86.87M | -5.38 | -41.15% | ― | -100.00% | 64.23% |
| NRXP | 45Neutral | $98.28M | -2.92 | 168.68% | ― | ― | 67.07% |
| IMUX | 43Neutral | $102.47M | -1.53 | -157.89% | ― | ― | 50.66% |
| ATYR | 41Neutral | $12.11M | -0.25 | -95.59% | ― | ― | 21.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | 7.34 | 0.43 | 6.21% | |
| ATYR | Atyr Pharma Inc. | 6.29 | -26.77 | -80.98% | |
| VTVT | vTv Therapeutics Inc. | 24.15 | -0.77 | -3.09% | |
| NRXP | Nrx Pharmaceuticals, Inc. | 2.17 | -0.57 | -20.80% | |
| EQ | Equillium | 1.38 | -0.06 | -4.17% | |
| HOWL | Werewolf Therapeutics, Inc. | 1.05 | -0.16 | -13.22% |
Immunic Corporate Events
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
NeutralOn September 9, 2026, Immunic hosted a Relapsing Multiple Sclerosis Research and Development Day webinar to present updates on its RMS program via a video conference held from 11:00 a.m. to 12:30 p.m. ET. The event highlighted the company’s dev...
Immunic Adds Veteran Finance Leader to Board
PositiveOn August 10, 2026, Immunic announced that it had appointed Elena Ridloff, CFA, to its board of directors, effective August 6, 2026, adding a director with more than two decades of experience in finance, capital markets and corporate development acro...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026